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Abstract: Tumour suppressor proteins, such as p53, BRCA1, and ABC, play key roles in preventing
the development of a malignant phenotype, but those that function as transcriptional regulators need
to enter the nucleus in order to function. The export of proteins between the nucleus and cytoplasm is
complex. It occurs through nuclear pores and exported proteins need a nuclear export signal (NES)
to bind to nuclear exportin proteins, including CRM1 (Chromosomal Region Maintenance protein
1), and the energy for this process is provided by the RanGTP/RanGDP gradient. Due to the loss of
DNA repair and cell cycle checkpoints, drug resistance is a major problem in cancer treatment, and
often an initially successful treatment will fail due to the development of resistance. An important
mechanism underlying resistance is nuclear export, and a number of strategies that can prevent
nuclear export may reverse resistance. Examples include inhibitors of CRM1, antibodies to the nuclear
export signal, and alteration of nuclear pore structure. Each of these are considered in this review.
Keywords: Nuclear export; CRM1; Ran; nucleocytoplasmic transport
1. Introduction
Cancer is a disease characterised by genetic mutations leading to uncontrollable cell division and
invasion into local tissue, which eventually spreads into distant tissue, a process known as metastasis.
Cancer is a very heterogeneous disease, although it has been proposed and widely accepted that
there are hallmark features common to most cancer cells (Figure 1) [1], the development of which is
driven by mutations. Mutations are acquired through either exogenous or endogenous DNA damage.
In response to DNA damage, the cell can activate DNA repair systems and enter cell cycle arrest in
order to limit further damage. A key component of this response is the p53 tumour suppressor gene
that controls cell cycle arrest, and which can also, if catastrophic damage occurs, induce apoptosis
(i.e., programmed cell death) [2]. These mechanisms prevent mutations from being passed onto
future generations of cells. As such, the rate of spontaneous mutations occurring in normal tissue
is low, although its exact incidence is difficult to measure [3]. The acquisition of mutations may be
viewed as a stepwise process and often there is a failure of DNA repair mechanisms. When these
mechanisms are disrupted, the cancer cells can acquire mutations at a rapid rate and acquire hallmark
features. This can be seen as a process of Darwinian natural selection, as a heterogeneous cancer cell
population includes cells that may become dominant due to favourable mutations [4]. An alternative
theory to the acquisition of mutations is that cancer cells revert to an ancient survival programme
under stress, which prioritizes the continuation of individual cellular life over that of the multicellular
organism [5]. This article focuses on drug resistance, which can be considered a result of the selection
pressure on cancer cells when exposed to chemotherapy [1]. There appears to be redundancy in
many signalling pathways, which the chemotherapeutic drugs target. When one pathway is shut off,
there may be residual function in another pathway, and this could be further enhanced by additional
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mutations [6]. Drug resistance in cancer cells is comparable to antibiotic resistance in the sense
that there are slow growing cancer stem cells that possess tumour initiation and self-renewal ability,
and can escape the effects of drug treatment by becoming quiescent, and are thus comparable to
populations of persister cells in microbial biofilms [7]. This article will focus on the mechanisms of
drug resistance, particularly with respect to nucleocytoplasmic transport, and potential targets in
overcoming resistance. Many tumour suppressor proteins and negative regulators of the cell cycle
need to be in the nucleus to regulate gene expression and promote apoptosis. Nuclear transport has
been an intensive area of research and the underlying mechanisms provide possible molecular targets
for therapeutic intervention. This review considers the structures and mechanisms involved in nuclear
export, and how the inhibition of nuclear export may be able to reverse drug resistance.
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These characteristics contribute towards the pathogenesis of cancer and may arise due to mutations.
2. Nuclear Export tr ct res and Mechanisms
Ther are a number ctures involved in the nucl ar export f proteins larger than 40 kDa
including the nuclear r c plex, nuclear export signals present on the protein to be exported,
karyopherins, and Ran. Each of these will be discussed in this section.
2.1. The Nuclear Pore and Nuclear Envelope
A key feature of eukaryote cells is compartmentalisation; organelles are separated from the
cytoplasm by membranes. Molecules can move between these compartments through specialised
transport pores. The nuclear envelope [8] is composed of an inner and outer membrane, it prevents
various macromolecules, including proteins, from freely moving into the nucleus from the cytoplasm.
The nucl ar envelope membranes are joined intermittently by nuclear p re complexes, the specialised
transport pores of the nucleus. These nuc ear pores control the entry and exit of macromolecules
from the nucl us [9], and allow small molecules and ions to freely diffus through, but not larger
molecules such as proteins and ribosomal subunits. Larger molecules instead move through the
nuclear pores in a selective, active process facilitated by a number of mobile transport receptors.
Nuclear pores are formed by a structure known as the nuclear pore complex that has a total molecular
mass of 125 mDa and contains up to 100 proteins known as nucleoporins (Nups). Nuclear pores have
a symmetrical structure with filaments on both sides, and those on the nuclear side form a basket [10]
(Figure 2). There are a variety of Nups; transmembrane Nups that anchor the nuclear pore complex
into the nuclear envelope, structural Nups, and FG Nups that contain repeating amino acid sequences
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composed of phenyalanine (F) and glycine (G). FG Nups have no secondary protein structure and
form filaments, they are localised to the central nuclear pore region of the nuclear pore complex, and
extend to filaments on its cytoplasmic and nucleoplasmic surface [11]. FG Nups, for example NUP 62
that is located on the cytoplasmic side of the nuclear membrane, have been shown to be involved in
transport across the pore.
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The entry and exit of macromolecules from the nucleus is regulated by this complex.
2.2. Nuclear Localisation and Export Signals
Nuclear import and export ar g verned by sp cific amino a id sequences in the targ t protein [12].
Sequences involved with import into the nucleus are called nuclear localisation signals (NLS), whilst
those involved with export out of the nucleus are called nuclear export signals (NES). There are
two types of NLSs, those con isting of a single pa t up to eight amino acids long and those consisting
of two distinct parts separated by a segment of 10 amino acids [13]. NESs consist of a hydrophobic
sequence characterised by a leucine-rich motif of amino acids. The typical spacing is LAAALAALAL
where L is leucine and A is any other amino acid [14].
2.3. Karyopherins
Proteins moving in or out of the nucleus must do so through the nuclear pore. Proteins larger
than 40 kDa cannot pass through via passive diffusion, but instead depend upon an active process
facilitated by a family of transport receptor molecules known as karyopherins [15]. Karyopherins are
mobile receptors that inte act with Nups to allow the moveme t f proteins thr ugh the nuclear pore,
and can be divided into importins and exportins that are, respectively, involved in importing and
exporting proteins. There are also transportins that can move in both directions. Nineteen karyopherins
have been identified to date. Chromosome maintenance protein 1 (CRM1) is the primary exportin
receptor. NESs bind to CRM1 with low affin ty and when NESs that bind with high affinity were over
expressed in vitro, the CRM1-NES complex became trapped in the filaments of the nuclear pore on the
cytoplasmic side. A possible explanation for the low affinity of the NES is that it enables CRM1-NES
export complex disassembly [16].
2.4. RanGTP
The movement facilitated by the karyopherins is an active process that requires energy.
This energy is supplied by the RanGTP binding proteins, which act as molecular switches that move
between an active GTP-bound state and an inactive GDP-bound state. Two processes are involved in
GTP–GDP cycling, hydrolysis and dissociation. In hydrolysis, there is destruction of a phosphate bond:
GTPÑGDP + Pi (phosphate). Dissociation causes the release of GDP from Ran and a free GTP will then
take its place if there are high levels of GTP in the cytoplasm. Ran possesses both intrinsic hydrolysis
and dissociation activities, although each occurs at a very low rate. There are two groups of regulators
Cancers 2016, 8, 35 4 of 11
that assist Ran in switching between the GTP- and GDP-bound states. The GTPase-activating proteins
(GAPs) cause a change in Ran conformation, increasing the rate of intrinsic hydrolysis of RanGTP to
the inactive GDP state (Figure 3). GTP hydrolysis is further stimulated by Ran binding proteins 1 and
2 (RanBP1 and RanBP2) [17]. Conversely, guanine nucleotide exchange factors (GEFs) bind to RanGDP
and catalyse the exchange to RanGTP. Hydrolysis and dissociation occur at an equal rate (Figure 3).
RCC1 (regulator of chromosome condensation) is the GEF for Ran, and is also involved in controlling
mitosis, as such it is bound to chromatin and is located within the nucleus [18]. RanGAP and RanBPs
are located in the cytoplasm, resulting in a concentration gradient with a higher concentration of
RanGTP in the nucleus and a higher concentration of RanGDP in the cytoplasm [19] (Figure 4).
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2.5. The Overall Export/Import Mechanism
The import mechanism begins with the formation of a complex in the cytoplasm between
importins such as importin-α/β and cargo proteins that have a nuclear localisation signal (NLS).
Once this complex has been formed karyopherins attach to the nuclear pore complex through
interactions with nucleoporins. When the complex reaches the nucleus, RanGTP causes the complex
to disassemble by binding to importin-β. The protein is then released into the nucleus, while the
importin-RanGTP moves into the cytoplasm through the nuclear pore. The converse is true for export
where a protein with a NES within the nucleus binds to an exportin and this in turn binds to RanGTP to
form a NES-exportin-RanGTP complex. The complex then translocates through the nuclear pore to the
cytoplasm. There is hydrolysis of the RanGTP to GDP and the complex dissociates releasing the protein
into the cytoplasm. Afterwards, Nup88 recruits the cytoplasmic CRM1 to nuclear pore filaments that
promote the recycling of CRM1 back to the nucleus so it can take part in export. This recycling occurs
in a temperature and Ran-independent manner [20–23].
3. The Role of Nuclear Export in Cancer and Drug Resistance
Excessive nuclear export may be a factor in the development of cancer and resistance to
chemotherapy. Consequently, inhibition of nuclear export is a potential area for treatment and reversion
of resistance. Modification of nuclear export can occur in a number of ways, principally through changes
to CRM1, the NES, and nuclear pore architecture. In this section each of these is looked at in turn.
3.1. CRM1 and Cancer
CRM1 is involved in the export of drug targets, tumour suppressors, and cell cycle inhibitors from
the nucleus to the cytoplasm and these CRM1-mediated events have been implicated in breast cancer.
BRAD1 (BRCA1-associated RING domain protein 1) has tumour suppressor features, and is exported
to the cytoplasm where it can exert pro-apoptotic effects. BRAD1 interacts with BRCA1 (breast cancer
type 1 susceptibility protein) and reduces the ability of the latter. Excessive export of BRCA1 via CRM1
from the nucleus to the cytoplasm can lead to the development of cancer [24]. CRM1 mediated export
has also been implicated in colon cancer through its interaction with the APC tumour suppressor, in
leukaemia via the BCR-ABL tumour suppressor, and export of p53 into the cytoplasm in a variety of
cancers [25–27].
3.2. CRM1 Inhibitors
Leptomycin B, a secondary metabolite of streptomyces bacteria, was the first CRM1 inhibitor to be
identified. It alkylates a reactive cysteine residue (cysteine 528) on CRM1, preventing it from binding
to the NES, and thus blocks export by preventing formation of the CRM1-NES-RanGTP complex.
Leptomycin B has been demonstrated to have efficacy in vitro and in animal models, although when
introduced to humans in a phase 1 clinical trial there was dose limiting toxicity with severe malaise
and anorexia [28]. A number of other CRM1 inhibitors have been developed, all of which act by
inactivating cysteine 528, examples include ratjadone analogs, synthetic leptomycin B derivatives and
selective inhibitors of nuclear export (SINE).
4. Application of CRM1 Inhibitors
4.1. Topoisomerase
During DNA transcription and replication, DNA becomes tangled due to its helical structure.
Topoisomerase unwinds DNA allowing the supercoiled structure to relax by temporarily inducing
strand breaks, through a process known as transesterification. Transesterification involves the formation
of a covalent bond between the tyrosol oxygen on the topoisomerase and a phosphate on the backbone
of the DNA, breaking the phosphodiester bond [29]. Afterwards, a reverse transesterification reaction
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occurs; oxygen exposed on the original DNA molecule reacts with the phosphate that becomes covalently
bound to the topoisomerase. This breaks the bond between the phosphate and topisomerase and restores
the phosphodieseter bond within the DNA molecule [29]. Topoisomerases are divided into type I and
type II. Type I topoisomerases cause single strand breaks while type II cause double stranded breaks.
Topoisomerases are essential for cell survival and without them DNA replication and transcription
cannot occur. They are highly expressed in proliferating cells and, as such, they present an ideal target
for chemotherapy. Naturally-occurring topoisomerase inhibitors target type II topoisomerase α and
cause arrest during the tranesterification stage leading to permanent double stranded breaks and cell
death. One such inhibitor is etoposide, which is used to treat lymphoma, myelomas and lung cancer.
However, resistance after a period of successful treatment is a common outcome, frequently due to
export of topoisomerase from the nucleus to the cytoplasm. When in the cytoplasm topoisomerase II α
cannot interact with DNA and so permanent double stranded breaks are not formed. Alternatively,
the cytoplasmic topoisomerase II may act as a buffer, preventing etoposide from reaching the nucleus
and thus resulting in resistance [30]. In vitro studies of drug resistant myeloma cells exposed to CRM1
inhibitors, such as ratjadone, have shown that they can be re-sensitised to etoposide [31].
4.2. Galectin-3
Galectin-3 (gal-3), a 30 kDa protein without enzymatic activity, is a member of theβ-galactoside-specific
lectin family. Gal-3 exhibits pleiotropic biological functions, especially in tumours. It has roles in
cell growth, apoptosis, adhesion, tumour angiogenesis, metastasis, cancer-matrix interactions and
drug resistance [32,33]. Gal-3 is found in different compartments in different cells types including
the nucleus, cytoplasm and on the cell surface. Its function is dictated by its location, as nuclear, but
not cytoplasmic galectin-3 can induce apoptosis [31]. It was shown that in cancer cells exposed to
the cytotoxic anticancer drug cisplatin, gal-3 was exported from the nucleus to the cytoplasm and
as a result apoptosis did not occur. In the same study when leptomycin B was added to these cells
galectin-3 could not be exported with CRM1 so it stayed in the nucleus, and apoptosis occurred after
exposure to cisplatin. A clinically acceptable CRM1 inhibitor could be used to complement a variety
of existing chemotherapies. However, the role of gal-3 in apoptosis has not been fully characterised,
and there is increased expression in breast cancer cells that makes them more resilient to apoptosis,
although both over and under-expression in macrophages leads to an increased rate of apoptosis [34,35].
Recent studies have revealed that gal-3 is up-regulated in Philadelphia chromosome-positive (Ph+)
chronic myeloid leukaemia (CML) and in precursor B-lineage acute lymphoblastic leukaemia (ALL)
after conditioning with bone marrow (BM) stromal cells [36,37]. Cheng and colleagues [38] reported
that, in patients with acute myeloid leukaemia (AML), higher bone marrow LGALS3 (gal-3) gene
expression was a prognostic factor for shorter overall survival. Gal-3 was recently reported to be
associated with an increase in drug resistance in chronic myeloid leukaemia (CML) mediated by
the bone marrow microenvironment [36]. Hu et al. (2015) [39] found that gal-3 was dramatically
up-regulated in human bone marrow-derived mesenchymal stromal cells (hBM-MSC)-conditioned
acute leukaemia cell lines, and that this was associated with the activation of β-catenin signalling.
Both gal-3 and β-catenin signalling were shown to be essential for the survival of acute leukaemia
cells (ALCs) after they were treated with cytotoxic drugs. The same group showed that gal-3
modulated β-catenin signalling by regulating GSK-3β phosphorylation and the PI3K/Akt pathway in
hBM-MSC-conditioned ALCs [39].
4.3. Selective Inhibitors of Nuclear Export (SINE)
Recently, a novel class of small molecule Selective Inhibitors of Nuclear Export (SINE) have
been developed, which bind specifically to the NES-binding groove of XPO1/CRM1 and prevent the
interaction with its cargo proteins [40–42]. These compounds showed anti-cancer activity in a number
of solid and haematological malignancies both in vitro and in vivo [40,41,43–50]. Selinexor (KPT-330),
a first-in-class selective inhibitor of nuclear export (SINE), has been developed by Karyopharma
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Therapeutics and is the most advanced pharmacological agent currently being evaluated in phase I/II
human clinical trials for haematological and solid tumours. SINE compounds have been shown to
selectively suppress tumour cells and spare normal cells in pre-clinical and clinical settings, both alone
and in combination with other drugs, and thus represent a novel therapy for patients at high risk of
metastasis and a novel class of anti-cancer agents [51–54].
5. NES Inhibitors
Survivin is a member of the inhibitors of apoptosis family and is involved in cell division through
its interactions with mitotic spindles. It is highly expressed in tumour and embryonic cells but not in
normal tissue. Increased expression levels correlate with tumour grade, resistance to chemotherapy
and overall survival. This makes it an ideal candidate for chemotherapy [55]. Survivin is exported from
the nucleus in a CRM1 dependent manner and only exerts an anti-apoptotic affect when present in the
cytoplasm. Evidence for this comes from in vivo experiments and the identification of nuclear survivin
in colorectal cancer specimens. Higher concentrations of nuclear survivin compared to cytoplasmic
survivin were associated with prolonged survival [56]. In the same study antibodies were produced
against the survivin NES preventing its nuclear export, resulting in increased apoptosis and reduced
resistance to chemotherapeutic agents such as cisplatin. Targeting NES to prevent nuclear export in
general provides a more specific target than CRM1 and since survivin is not expressed in normal cells
it is, in theory, less likely to produce side effects in patients compared to CRM1 inhibitors.
5. Nup Dormancy and Resistance
During cisplatin treatment of ovarian cancer cells, it was shown that some cells gain resistance
to treatment and enter a transient state of dormancy. Some dormant cells then resume proliferation
and eventually lose their resistance to cisplatin treatment. One study has shown that a possible cause
of this transient increase in resistance and reduction in proliferation is the modification of a Nup
protein. Nup62 is present on the nuclear side of the nuclear pore complex. It has FG regions and thus
is involved in transport through the nuclear pore [57]. Small interfering RNA was used to knock down
Nup62 expression, leading to a reversible inhibition of growth [57]. However, when Nup62 expression
was knocked down in combination with cisplatin treatment, the ovarian cells gained resistance to
treatment and entered a state of dormancy. Afterwards, when transient Nup62 expression was induced,
the cells left their state of dormancy and proliferated rapidly. A potential treatment for these dormant
cells may be gene therapy to replace the mutated Nup62 gene.
6. Sgk1
It has been shown that serum- and glucocorticoid-regulated kinase (Sgk1) regulates RanBP1
transcription. RanBP1 is a major effector of Ran and could potentially be a target for cancer therapy [58].
Talarico et al. (2015) demonstrated that a selective Sgk1 inhibitor named SI113 blocked cell cycle
progression in two human hepatocarcinoma (HCC) cell lines, HepG2 and HuH-7. They consider that
Sgk1 overexpression may have a central role in cancer due to its ability to regulate the Ran/RanBP1
pathway. SI113 targets and inhibits Sgk1 which turns off several pathways, including Ran/RanBP1,
leading to tumour growth arrest and the induction of apoptosis and necrosis. This compound appears
to have a good therapeutic index as there were only minimal signs of toxicity in vitro or in SI113-treated
mice [59].
7. Conclusions
Drug resistance is a growing problem in oncology, due to the continued accumulation of mutations
by cancer cells. Nuclear export is a potential area from which resistance can arise. The structure of
the nuclear pore complex has been elucidated and the mechanisms involved in the export of proteins
have been well documented. However, there are gaps in our knowledge of this area, especially with
regard to the structural characteristics of FG nucleoporins. Drug resistance via nuclear export can
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only be understood with an appreciation of the structures involved. The inhibition of CRM1 has been
the focus of most strategies to overcome drug resistance, although leptomycin B treatment has been
disappointing due to toxic side effects on patients. Alternative CRM1 inhibitors have been developed
which are superior in vitro. SINE inhibitors are currently undergoing clinical evaluation and results
from these trials seem promising. Inhibition of the NES using antibodies is a promising area as it is
a more specific treatment, however little work has been done in this area.
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